How is Darzalex used?
Darzalex™ (daratumumab, Janssen/Genmab) is a monoclonal antibody. It is approved for use in the treatment of multiple myeloma patients:
- In combination with the medicines lenalidomide and dexamethasone, or bortezomib and dexamethasone, in people who have received at least one prior medicine to treat multiple myeloma.
- Alone in people who have received at least three prior medicines to treat multiple myeloma, including a proteasome inhibitor and an immunomodulatory agent, or who did not respond to a proteasome inhibitor and an immunomodulatory agent.
What types of patients can benefit from Darzalex?
Darzalex has been studied in a variety of patients with relapsed and/or refractory myeloma including:
- Patients who have received several prior therapies (heavily pretreated)
- Patients who were refractory to both proteasome inhibitors and IMiDs
- Patients who previously received high-dose chemotherapy and stem cell transplant
- Patients with reduced kidney function (renal impairment)
- Patients with mildly reduced liver function (mild hepatic impairment)
How does Darzalex work?
Darzalex binds to CD38, a marker found on the surface of myeloma cells. It is thought to inhibit myeloma cell growth in several ways, including by directly affecting myeloma cells and by enabling immune cells to kill myeloma cells.